Quotient Sciences Translational Pharmaceuticals Quotient Sciences Translational Pharmaceuticals

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"BeiGene","sponsor":"Amgen Inc","pharmaFlowCategory":"D","amount":"$2,800.0 million","upfrontCash":"$2,800.0 million","newsHeadline":"Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"BeiGene"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Peptide","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Visen Pharmaceuticals"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Ascendis Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Peptide","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Visen Pharmaceuticals"},{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Renhui Bio Announced that the Application for the Marketing of Benaglutide Injection for Weight Loss Indications has been Accepted in China","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Peptide","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Shanghai Renhui Biopharmaceutical"},{"orgOrder":0,"company":"Shanghai Renhui Biopharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The Clinical Application for the New Pump Administration Method of Benaglutide for Weight Loss Indications was Approved","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Peptide","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Peptide","graph2":"Shanghai Renhui Biopharmaceutical"}]

    Find Approved Endocrinology Drugs in Clinical Development in CHINA

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Visen Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin

              Details:

              ACP-011 (lonapegsomatropin), a long-acting prodrug of unmodified somatropin is being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China.

              Lead Product(s): Lonapegsomatropin

              Therapeutic Area: Endocrinology Product Name: ACP-011

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Ascendis Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 17, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Visen Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to D...

              Details:

              Top-line results of TransCon hGH, from the trial indicate that lonapegsomatropin was well-tolerated and with comparable safety to daily growth hormone. The safety profile of lonapegsomatropin in Chinese children with GHD was consistent.

              Lead Product(s): Lonapegsomatropin

              Therapeutic Area: Endocrinology Product Name: TransCon hGH

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Shanghai Renhui Biopharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Renhui Bio Announced that the Application for the Marketing of Benaglutide Injection for Weight Loss Indications has been Accepted in China

              Details:

              Yishengtai (benaglutide) is a fully human GLP-1 drug, which mainly used for weight loss effect in the clinical use of type 2 diabetes and comprehensive benefits for overweight and mechanisms such as enhancing satiety, delaying gastric emptying.

              Lead Product(s): Beinaglutide

              Therapeutic Area: Endocrinology Product Name: Yishengtai

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Shanghai Renhui Biopharmaceutical

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The Clinical Application for the New Pump Administration Method of Benaglutide for Weight Loss Indications was Approved

              Details:

              Yishengtai (benaglutide) is a fully human GLP-1 drug, which mainly used for weight loss effect in the clinical use of type 2 diabetes and comprehensive benefits for overweight and mechanisms such as enhancing satiety, delaying gastric emptying.

              Lead Product(s): Beinaglutide

              Therapeutic Area: Endocrinology Product Name: Yishengtai

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              BeiGene

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

              Details:

              The stratagic collaboration between Amgen and BeiGene will significantly accelerate Amgen's plans to expand its oncology presence in China.

              Lead Product(s): Denosumab

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Amgen Inc

              Deal Size: $2,800.0 million Upfront Cash: $2,800.0 million

              Deal Type: Collaboration January 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Douglas Pharma, a New Zealand success story, with CDMO capabilities for softgels, liquids, tablets, capsules & powders.
              Post Enquiry
              POST ENQUIRY